{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:40:10Z","timestamp":1792644010271,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007835","name":"Wenzhou Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007835","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204217"],"award-info":[{"award-number":["82204217"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejmech.2026.119296","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:41:09Z","timestamp":1788417669000},"page":"119296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design and synthesis of novel peptide-based degraders against wild type and gatekeeper mutants FGFR1 for the treatment of NSCLC"],"prefix":"10.1016","volume":"320","author":[{"given":"Ziyu","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luwei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanxuan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4121-1360","authenticated-orcid":false,"given":"Yizhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenju","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuepao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2710-0966","authenticated-orcid":false,"given":"Shijie","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119296_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2026.119296_bib2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119296_bib3","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ejmech.2026.119296_bib4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41392-020-00251-2","article-title":"Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth","volume":"5","author":"Yao","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119296_bib5","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ccell.2022.09.018","article-title":"Squamous cell lung cancer: current landscape and future therapeutic options","volume":"40","author":"Lau","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.119296_bib6","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc.2017.84","article-title":"Understanding and targeting resistance mechanisms in NSCLC","volume":"17","author":"Rotow","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.119296_bib7","doi-asserted-by":"crossref","first-page":"62ra93","DOI":"10.1126\/scitranslmed.3001451","article-title":"Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer","volume":"2","author":"Weiss","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.119296_bib8","first-page":"803","article-title":"Prognostic value of FGFR1 gene copy number in patients with non-small cell lung cancer: a meta-analysis","volume":"6","author":"Yang","year":"2014","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.ejmech.2026.119296_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19071875","article-title":"FGF family: from drug development to clinical application","volume":"19","author":"Hui","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119296_bib10","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1200\/JCO.2012.43.8622","article-title":"Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer","volume":"31","author":"Kim","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119296_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jtho.2015.08.003","article-title":"FGFR signaling as a target for lung cancer therapy","volume":"11","author":"Desai","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2026.119296_bib12","doi-asserted-by":"crossref","first-page":"15905","DOI":"10.1002\/anie.202101328","article-title":"Discovery of a potent degrader for fibroblast growth factor receptor 1\/2","volume":"60","author":"Du","year":"2021","journal-title":"Angew. Chem.Int. Edit."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119296_bib13","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.tips.2025.09.004","article-title":"Next-generation isoform-selective fibroblast growth factor receptor inhibitors","volume":"46","author":"Chen","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119296_bib14","doi-asserted-by":"crossref","first-page":"14627","DOI":"10.1021\/acs.jmedchem.6c00585","article-title":"Structure-based design and optimization of novel, potent and selective covalent FGFR2\/3 inhibitors with a tricyclic core","volume":"69","author":"Lu","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119296_bib15","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1158\/1078-0432.CCR-17-0645","article-title":"A phase Ib open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers","volume":"23","author":"Paik","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119296_bib16","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.119296_bib17","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119296_bib18","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1021\/acschembio.5b00014","article-title":"Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy","volume":"10","author":"Sohl","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119296_bib19","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1158\/1541-7786.MCR-18-0429","article-title":"The FGFR1 V561M gatekeeper mutation drives AZD4547 resistance through STAT3 activation and EMT","volume":"17","author":"Ryan","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119296_bib20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","article-title":"The changing treatment landscape of EGFR-mutant non-small-cell lung cancer","volume":"22","author":"Zhou","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119296_bib21","article-title":"From challenges to solutions: a review of fourth-generation EGFR tyrosine kinase inhibitors to overcome the C797S triple mutation in non-small cell lung cancer","volume":"15","author":"Ahmad","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119296_bib22","article-title":"A stapled peptide inhibitor targeting the binding interface of N6\u2010Adenosine\u2010Methyltransferase subunits METTL3 and METTL14 for cancer therapy","volume":"63","author":"Li","year":"2024","journal-title":"Angew. Chem., Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119296_bib23","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s12276-023-01016-x","article-title":"Peptides as multifunctional players in cancer therapy","volume":"55","author":"Vadevoo","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejmech.2026.119296_bib24","article-title":"Enhanced screening via a pure DNA-encoded peptide library enabled by an Fmoc modification","volume":"123","author":"He","year":"2026","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2026.119296_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/v13040649","article-title":"Phage-displayed peptides for targeting tyrosine kinase membrane receptors in cancer therapy","volume":"13","author":"Aloisio","year":"2021","journal-title":"Viruses-Basel"},{"key":"10.1016\/j.ejmech.2026.119296_bib26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41392-020-00315-3","article-title":"Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials","volume":"5","author":"Lu","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119296_bib27","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41586-022-04654-9","article-title":"Design of protein-binding proteins from the target structure alone","volume":"605","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119296_bib28","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1021\/acscentsci.3c00364","article-title":"Stretching peptides' potential to target protein-protein interactions","volume":"9","author":"Venneti","year":"2023","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2026.119296_bib29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic peptides: current applications and future directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119296_bib30","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.119296_bib31","article-title":"Recent advances in peptide-drug conjugates as anticancer agents","volume":"15","author":"Feng","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119296_bib32","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41392-024-02107-5","article-title":"Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines","volume":"10","author":"Xiao","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"17","key":"10.1016\/j.ejmech.2026.119296_bib33","doi-asserted-by":"crossref","first-page":"15373","DOI":"10.1021\/acs.jmedchem.4c00967","article-title":"Chemoenzymatic synthesis of DNP-functionalized FGFR1-Binding peptides as novel peptidomimetic immunotherapeutics for treating lung cancer","volume":"67","author":"Li","year":"2024","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119296_bib34","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.chembiol.2021.04.011","article-title":"Targeted protein degradation: a promise for undruggable proteins","volume":"28","author":"Samarasinghe","year":"2021","journal-title":"Cell Chem. Biol."},{"issue":"41","key":"10.1016\/j.ejmech.2026.119296_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202511467","article-title":"HerTACs enable tumor\u2010selective lysosomal degradation of membrane and extracellular proteins","volume":"64","author":"He","year":"2025","journal-title":"Angew. Chem., Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119296_bib36","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-021-00770-1","article-title":"LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation","volume":"17","author":"Ahn","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119296_bib37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119296_bib38","article-title":"Development of glucagon-like Peptide-1 lysosomal targeting chimeras for degradation of extracellular and membrane proteins","volume":"5","author":"Zhu","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119296_bib39","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.bbamcr.2008.10.016","article-title":"Sorting of lysosomal proteins","volume":"1793","author":"Braulke","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2026.119296_bib40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0092-8674(01)00299-9","article-title":"The GGAs promote ARF-dependent recruitment of clathrin to the TGN","volume":"105","author":"Puertollano","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119296_bib41","doi-asserted-by":"crossref","first-page":"19107","DOI":"10.1021\/jacs.3c07687","article-title":"Harnessing the lysosomal sorting signals of the cation-independent Mannose-6-Phosphate receptor for targeted degradation of membrane proteins","volume":"145","author":"Yu","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.119296_bib42","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1039\/D0OB00265H","article-title":"Protein labeling approach to improve lysosomal targeting and efficacy of antibody-drug conjugates","volume":"18","author":"Han","year":"2020","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2026.119296_bib43","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41580-018-0001-6","article-title":"The coming of age of chaperone-mediated autophagy","volume":"19","author":"Kaushik","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"18","key":"10.1016\/j.ejmech.2026.119296_bib44","article-title":"Targeted degradation of cell-surface proteins via ChaperoneMediated autophagy by using peptide-conjugated antibodies","volume":"63","year":"2023","journal-title":"Angew. Chem., Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119296_bib45","doi-asserted-by":"crossref","first-page":"16377","DOI":"10.1021\/jacs.1c08521","article-title":"Covalently engineered nanobody chimeras for targeted membrane protein degradation","volume":"143","author":"Zhang","year":"2021","journal-title":"J. Am. Chem. Soc."},{"issue":"23","key":"10.1016\/j.ejmech.2026.119296_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202500311","article-title":"A self\u2010assembling LYTAC mediates CTGF degradation and remodels inflammatory tumor microenvironment for triple\u2010negative breast cancer therapy","volume":"12","author":"Lin","year":"2025","journal-title":"Adv. Sci."},{"issue":"8051","key":"10.1016\/j.ejmech.2026.119296_bib47","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41586-024-07947-3","article-title":"Transferrin receptor targeting chimeras for membrane protein degradation","volume":"638","author":"Zhang","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119296_bib48","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2213090120","article-title":"Gatekeeper mutations activate FGF receptor tyrosine kinases by destabilizing the autoinhibited state","volume":"120","author":"Besch","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2026.119296_bib49","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2147\/DDDT.S129991","article-title":"Insight into resistance mechanisms of AZD4547 and E3810 to FGFR1 gatekeeper mutation via theoretical study","volume":"11","author":"Liang","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2026.119296_bib50","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1002\/ijc.30848","article-title":"Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia\/lymphomas","volume":"141","author":"Cowell","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.ejmech.2026.119296_bib51","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.1021\/acs.jmedchem.5c00124","article-title":"Discovery of novel 2,4,5-Trisubstituted pyrimidine derivatives as potent and selective FGFR inhibitors against gatekeeper mutants for the treatment of NSCLC","volume":"68","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"issue":"48","key":"10.1016\/j.ejmech.2026.119296_bib52","doi-asserted-by":"crossref","first-page":"32933","DOI":"10.1021\/jacs.4c06160","article-title":"Conditionally activatable chimeras for tumor-specific membrane protein degradation","volume":"146","author":"Liu","year":"2024","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119296_bib53","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/s41467-025-56648-6","article-title":"A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy","volume":"16","author":"Xiao","year":"2025","journal-title":"Nat. Commun."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:25:50Z","timestamp":1792643150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426007415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":53,"alternative-id":["S0223523426007415"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119296","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and synthesis of novel peptide-based degraders against wild type and gatekeeper mutants FGFR1 for the treatment of NSCLC","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119296","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119296"}}